Print
Email
Print Edition Stories
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Biotech startup AlloCure Inc., a developer of cell therapy to treat kidney disease, has named Robert Brenner as its new president and CEO to lead the company in its new Burlington headquarters. Brenner takes over the position from John Wirthlin, who will serve as the company’s chief operating officer.
Prior to being named AlloCure’s CEO, Brenner served as senior vice president of medical affairs at AMAG Pharmaceuticals Inc., where he oversaw the nephrology clinical development activities. Before that, he worked at Amgen Inc. as executive director and renal anemia global program area leader. Brenner earned his M.D. from Albert Einstein College of Medicine.
AlloCure has finished enrollment for its Phase 1 trial to treat acute kidney injury with its bone marrow-derived stem cell therapy.
Founded in 2008, AlloCure was previously known as NephroGen. The company has two laboratory locations in Salt Lake City, Utah, and Hamburg, Germany. It pulled in a $14.5 million Series A funding round in July 2008, from SV Life Sciences and Novo A/S.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
